Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products. It is primarily developing Northera (droxidopa), a therapeutic agent that is used for the treatment of symptomatic neurogenic orthostatic hypotension (Neurogenic OH) in patients with primary autonomic failure, dopamine- -hydroxylase, and deficiency and non-diabetic autonomic neuropathy. The company is also evaluating the potential therapeutic applications of droxidopa in reducing the frequency of falls in patients with Neurogenic OH associated with Parkinson s disease, as well as other potentially norepinephrine-related conditions and diseases, including intradialytic hypotension, fibromyalgia, and adult attention deficit hyperactivity disorder. In addition, it engages in developing a portfolio of metabolically inert antifolates for the treatment of rheumatoid arthritis, and for the treatment of multiple other autoimmune disorders, including psoriasis, Crohn s disease, uveitis, ankylosing spondylitis, inflammatory bowel disease, cancer, and other immunological disorders. Chelsea Therapeutics International, Ltd. was founded in 2002 and is headquartered in Charlotte, North Carolina.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for CHTP